154 related articles for article (PubMed ID: 20195683)
21. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Yoshikawa T; Terashima M; Mizusawa J; Nunobe S; Nishida Y; Yamada T; Kaji M; Fukushima N; Hato S; Choda Y; Yabusaki H; Yoshida K; Ito S; Takeno A; Yasuda T; Kawachi Y; Katayama H; Fukuda H; Boku N; Sano T; Sasako M
Lancet Gastroenterol Hepatol; 2019 Mar; 4(3):208-216. PubMed ID: 30679107
[TBL] [Abstract][Full Text] [Related]
22. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.
Yamaue H; Shimizu A; Hagiwara Y; Sho M; Yanagimoto H; Nakamori S; Ueno H; Ishii H; Kitano M; Sugimori K; Maguchi H; Ohkawa S; Imaoka H; Hashimoto D; Ueda K; Nebiki H; Nagakawa T; Isayama H; Yokota I; Ohashi Y; Shirasaka T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):813-823. PubMed ID: 28251282
[TBL] [Abstract][Full Text] [Related]
23. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
[TBL] [Abstract][Full Text] [Related]
24. Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo.
Arai W; Hosoya Y; Haruta H; Kurashina K; Saito S; Hirashima Y; Yokoyama T; Zuiki T; Sakuma K; Hyodo M; Yasuda Y; Nagai H; Shirasaka T
Int J Clin Oncol; 2008 Dec; 13(6):515-20. PubMed ID: 19093179
[TBL] [Abstract][Full Text] [Related]
25. [Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].
Takebayashi K; Kawai Y; Tagi T; Matsumura M; Shimizu K; Yamamoto H; Mekata E; Tani T; Sato M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):385-7. PubMed ID: 22421764
[TBL] [Abstract][Full Text] [Related]
26. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.
Tamura S; Fujitani K; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Furukawa H;
Oncology; 2011; 80(5-6):296-300. PubMed ID: 21778769
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant Chemotherapy with S-1 plus Cisplatin for Patients with Stage III Gastric Cancer After Curative Resection.
Mita K; Ito H; Ota E; Takahashi K; Hashimoto M; Asakawa H; Hayashi T; Fujino K
Anticancer Res; 2017 Mar; 37(3):1329-1333. PubMed ID: 28314299
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer.
Inoue K; Nakane Y; Kogire M; Fujitani K; Kimura Y; Imamura H; Tamura S; Okano S; Kwon AH; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
Eur J Surg Oncol; 2012 Feb; 38(2):143-9. PubMed ID: 22154885
[TBL] [Abstract][Full Text] [Related]
29. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
30. A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.
Kimura Y; Kikkawa N; Iijima S; Kato T; Naoi Y; Hayashi T; Tanigawa T; Yamamoto H; Kurokawa E
Gastric Cancer; 2003; 6 Suppl 1():34-9. PubMed ID: 12775018
[TBL] [Abstract][Full Text] [Related]
31. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
Fushida S; Fujimura T; Oyama K; Yagi Y; Kinoshita J; Ohta T
Anticancer Drugs; 2009 Sep; 20(8):752-6. PubMed ID: 19543076
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301.
Okumura N; Soh J; Suzuki H; Nakata M; Fujiwara T; Nakamura H; Sonobe M; Fujinaga T; Kataoka K; Gemba K; Kataoka M; Hotta K; Yoshioka H; Matsuo K; Sakamoto J; Date H; Toyooka S
BMC Cancer; 2021 May; 21(1):506. PubMed ID: 33957881
[TBL] [Abstract][Full Text] [Related]
33. Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
Kim JY; Shin E; Kim JW; Lee HS; Lee DW; Kim SH; Lee JO; Kim YJ; Kim JH; Bang SM; Ahn SH; Park DJ; Lee JS; Lee JS; Kim HH; Lee KW
PLoS One; 2015; 10(3):e0120324. PubMed ID: 25793299
[TBL] [Abstract][Full Text] [Related]
34. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status.
Jeung HC; Rha SY; Shin SJ; Ahn JB; Noh SH; Roh JK; Chung HC
Br J Cancer; 2007 Aug; 97(4):458-63. PubMed ID: 17653073
[TBL] [Abstract][Full Text] [Related]
36. Impact of S-1 plus Cisplatin Neoadjuvant Chemotherapy on Scirrhous Gastric Cancer.
Kunisaki C; Makino H; Kimura J; Takagawa R; Kanazawa A; Ota M; Kosaka T; Ono HA; Akiyama H; Endo I
Oncology; 2015; 88(5):281-8. PubMed ID: 25591954
[TBL] [Abstract][Full Text] [Related]
37. [A case of successful S-1 alternate-day administration for far-advanced remnant gastric cancer].
Kashima Y; Adachi T; Hara N; Sohtome I; Shirasaka T
Gan To Kagaku Ryoho; 2012 Mar; 39(3):469-72. PubMed ID: 22421782
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery.
Kanazawa Y; Kato S; Fujita I; Onodera H; Uchida E
J Nippon Med Sch; 2013; 80(5):378-83. PubMed ID: 24189356
[TBL] [Abstract][Full Text] [Related]
39. Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
Hata Y; Kiribayashi T; Kishi K; Nagashima M; Nakayama T; Ikeda S; Kadokura M; Ozeki Y; Otsuka H; Murakami Y; Takagi K; Iyoda A
BMC Cancer; 2017 Aug; 17(1):581. PubMed ID: 28851314
[TBL] [Abstract][Full Text] [Related]
40. Toxic epidermal necrolysis associated with TS-1 in a patient with gastric cancer.
Tan CS; Lim R; Lim TC; Aw CW; Yeo SW; Lee SC
Jpn J Clin Oncol; 2011 May; 41(5):666-8. PubMed ID: 21415005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
